Biotechnology company Circa Group has announced a partnership with formulation science consultancy iFormulate, to support the upcoming launch of new biosolvent Cyrene®.
Cyrene® is a chiral dipolar aprotic solvent, a bio-based alternative to polar aprotic solvents such as NMP, DCM and DMF, which are under regulatory pressure worldwide due to their toxicity.
With a unique property set including viscosity, surface tension and polarities, Cyrene® is an interesting prospect for producing advanced materials. Over two years of testing and trialling Cyrene® with researchers and companies has yielded some promising results to date, showing Cyrene® as a safer, healthier, high-performance alternative to traditional solvents.
By collaborating with iFormulate, Circa will better understand its customers’ formulation needs and help them develop new products.
Commenting on the partnership, Dr. Jeff Eaves, General Manager at Circa subsidiary company Circa Sustainable Chemicals UK, said, “The market understands there is no direct drop-in replacement for traditional, toxic solvents – therefore process and formulation trials are crucial for developing bio-based alternatives. As Cyrene® is introduced across the market, we are grateful for iFormulate’s considerable industry experience and strong reputation as expert consultants to formulators across the UK and Europe. We look forward to using their formulation knowledge to support our customers.”
Dr. David Calvert, Director and co-founder of iFormulate, added, “Sustainability is a critical driver for many new formulation programmes. We have followed the development of Cyrene® over a number of years and are looking forward to helping the Circa team as they work with customers across a number of the formulation sectors.